MOUD Buprenorphine Subli denied for missing prior authorization by Centene?

Mirrors state Medicaid PDLs. Most state Medicaid programs (post-2023 X-waiver removal) allow PCP prescribing without specialist gatekeeping.

MATA Act 2022 / DATA 2000 X-waiver removal — any DEA-registered prescriber may prescribe buprenorphine. ASAM NPG OUD 2020 first-line. SAMHSA TIP 63 supports doses >24 mg for fentanyl-era patients. EPSDT for under-21.

## Why Centene Issued This Denial

Centene requires prior authorization for sublingual buprenorphine used as Medication for Opioid Use Disorder (MOUD). When a prescription is filled without an approved PA on file, the claim is automatically denied at the pharmacy. This denial is extremely common and does not reflect a judgment that the medication is not medically necessary — it reflects a process step that was not completed before dispensing.

Centene operates numerous Medicaid managed-care plans across many states. For Medicaid enrollees, federal rules around timely access to MOUD, combined with MHPAEA parity requirements, significantly limit the scope of PA requirements Centene may impose. Your appeal should reference both the specific plan's PA criteria and the applicable federal and state access standards.

## Why This Denial Is Appealable

PA denials are routinely overturned when the clinical record documents that the patient meets every criterion in Centene's PA policy. If the PA was not filed in advance, a retrospective exception request on medical grounds is the first step. If Centene's PA criteria exceed what is clinically supported by the FDA label or applicable guidelines, a MHPAEA challenge is available.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline in the denial letter. Centene must respond within 30 days (standard) or 72 hours (expedited/urgent).
• External review (ACA §2719 / ERISA §503): Available after exhausting internal appeals — generally within four months of the final internal denial.
• Medicaid fair hearing: For Centene Medicaid plans, the member also has the right to request a state Medicaid fair hearing, which runs on a separate and sometimes faster track.
• Expedited review: Strongly consider requesting expedited processing given the clinical risks associated with MOUD interruption.

## Concrete Appeal Steps

1. Obtain Centene's PA criteria / clinical coverage policy for buprenorphine MOUD for the specific plan. 2. Review whether a PA request was submitted — if not, request a retrospective exception and document the clinical circumstances that led to the missed PA. 3. Have the prescriber prepare a medical-necessity letter addressing each PA criterion by name, with specific chart references and dates. 4. Include all required supporting documentation (see below). 5. File a Medicaid fair hearing request in parallel if this is a Medicaid plan. 6. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Centene's PA criteria / clinical policy for buprenorphine MOUD
• Prescriber's medical-necessity letter addressing each PA criterion with chart citations
• Confirmed opioid use disorder diagnosis with dates
• Prior treatment history with outcomes
• Clinical severity documentation from the chart
• Prescriber credentials confirming qualification to prescribe buprenorphine for OUD
• FDA prescribing label for the specific sublingual product

## Criteria-Mapping Structure

For every requirement in Centene's PA policy, provide the matching chart evidence:

| Centene PA Requirement | Chart Evidence | |---|---| | Confirmed OUD diagnosis | Dated chart note + ICD-10 code | | Prescriber qualification documented | Credentialing records | | Treatment plan on file | Signed care plan / treatment agreement | | Prior treatment history (if required by policy) | List of prior treatments, dates, outcomes | | Clinical severity supports MOUD | Assessment notes, clinical progress notes |